Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.
Pachner
A R
AR
Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.
D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics / Q000627:therapeutic use; D000906:Antibodies / Q000032:analysis* / Q000276:immunology; D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D019204:GTP-Binding Proteins / Q000276:immunology; D006801:Humans; D007118:Immunoassay / Q000379:methods* / Q000592:standards; D015151:Immunoblotting; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D064547:Myxovirus Resistance Proteins; D009462:Neurology; D009500:Neutralization Tests; D011506:Proteins / Q000276:immunology; D017471:Receptors, Interferon / Q000187:drug effects; D011994:Recombinant Proteins; D017211:Treatment Failure
D000276:Adjuvants, Immunologic; D000906:Antibodies; D064547:Myxovirus Resistance Proteins; D011506:Proteins; D017471:Receptors, Interferon; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D019204:GTP-Binding Proteins; D000068556:Interferon beta-1a